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Advances in pediatric and obstetric surgery have resulted in an increase in the duration and
complexity of anesthetic procedures. A great deal of concern has recently arisen regard-
ing the safety of anesthesia in infants and children. Because of obvious limitations, it is
not possible to thoroughly explore the effects of anesthetic agents on neurons in vivo in
human infants or children. However, the availability of some advanced pre-clinical research
approaches and models, such as imaging technology both in vitro and in vivo, stem cells,
and non-human primate experimental models, have provided potentially invaluable tools
for examining the developmental effects of anesthetic agents. This review discusses the
potential application of some sophisticated research approaches, e.g., calcium imaging, in
stem cell-derived in vitro models, especially human embryonic neural stem cells, along
with their capacity for proliferation and their potential for differentiation, to dissect relevant
mechanisms underlying the etiology of the neurotoxicity associated with developmental
exposures to anesthetic agents. Also, this review attempts to discuss several advantages
for using the developing rhesus monkey model (in vivo), when combined with dynamic
molecular imaging approaches, in addressing critical issues related to the topic of pedi-
atric sedation/anesthesia. These include the relationships between anesthetic-induced
neurotoxicity, dose response, time-course, and developmental stage at time of exposure
(in vivo studies), serving to provide the most expeditious platform toward decreasing the
uncertainty in extrapolating pre-clinical data to the human condition.
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INTRODUCTION
Anesthetic drugs have been used for many years in pediatric
patients without clinical evidence of adverse central nervous sys-
tem sequelae. It is known that the most frequently used general
anesthetics have either NMDA-type glutamate receptor block-
ing or GABA receptor enhancing properties. There is mounting
and convincing pre-clinical evidence in animal models that anes-
thetics in common clinical use are neurotoxic to the developing
brain; and accumulated data (Choi, 1988; Ikonomidou et al., 1999;
Jevtovic-Todorovic et al., 2003; Wang et al., 2005, 2006) indicate the
involvement of NMDA-type glutamate receptors in the etiology
of neurotoxic effects of anesthetic agents. The clinical relevance of
anesthetic neurotoxicity is an urgent public health matter.
Recent advances in our understanding of stem cell biology
and neuroscience have opened up new avenues of research for
detecting anesthetic-induced neurotoxicity, dissecting underly-
ing mechanisms, and developing potential protection/prevention
strategies against anesthetic-induced neuronal injury. The appli-
cation of stem cell biology/models toward understanding issues
relevant to developmental neurotoxicology has the potential to
advance our understanding of brain-related biological processes,
including neuronal plasticity and toxicity (Keirstead et al., 2005;
Li et al., 2005; Lamba et al., 2006; Lee et al., 2006; Kang et al.,
2007). This review discusses several advantages and important
issues for using stem cells as models and advanced research
approaches, e.g., calcium imaging, for addressing critical issues
related to the toxicity of pediatric anesthetics. These include
the relationships between drug-induced neurotoxicity and how
stem cells can be used as tools for dissecting out mechanisms
underlying pharmacological and toxicological phenomena during
development.
The general anesthesia drug products have been used for many
years in pediatric patients without direct clinical evidence of
adverse central nervous system sequelae. Data in support of a
correlation between surgery and subsequent neuro-physiological
changes has accumulated over years. The use of a non-human
primate model to decrease the uncertainty in extrapolating pre-
clinical data (Slikker et al., 2007; Zou et al., 2009a; Brambrink et al.,
2010) to the human condition (e.g., peri-operative neurotoxicity)
continues to garner considerable interest among anesthesiolo-
gists and toxicologists, with growing recognition to be anticipated
from surgeons and neonatologists. A host of mechanistic studies
have been completed or are underway which have been helpful
in providing rationale for the overall concern over anesthetic and
sedative-induced neurotoxicity. These studies have been and will
be instrumental in teasing apart the causalities, refining hypothe-
ses, developing alternative or protective measures, and suggesting
clinical strategies for assessing the phenomena in children. Such
studies have ranged from cell culture to histopathology, behav-
ioral tests to molecular imaging (in vivo) studies – including
non-human primate (Xie and Tanzi, 2006; Slikker et al., 2007;
Rizzi et al., 2010; Paule et al., 2011). Because it is difficult or
www.frontiersin.org October 2012 | Volume 3 | Article 142 | 1
Wang Approaches, models, and pediatric anesthesia
impossible to disentangle the effect of anesthesia per se from
the effects of surgery or preexisting pathologies that necessitate
surgery, it is essential to continue studies in non-human primates
in order to obtain valuable information on the time-course and
severity of observed deficits. It will also be necessary to deter-
mine whether the injured brain can recover with no or minimal
loss of function, or whether the injured brain can be protected
from sedative/anesthetic-induced injury by the co-administration
of anti-oxidants or other agents. In addition, the development of
PET/CT imaging systems provide the ability to collect dynamic,
sensitive, and quantitative three-dimensional molecular informa-
tion from the brains of living subjects including non-human
primates and humans.
STEM CELL-DERIVED MODELS (IN VITRO), CALCIUM
IMAGING, AND UNDERLYING MECHANISMS OF
ANESTHETIC-INDUCED NEUROTOXICITY
Advances in our understanding of stem cell biology and neuro-
science have opened up new avenues of research for detecting early
life stress-induced neurotoxicity and developing potential pro-
tection/prevention strategies against toxicant-induced neuronal
injuries (Kiss et al., 1994; Wang et al., 1994, 1996; Brokhman
et al., 2008; Trujillo et al., 2009). The classic definition of a stem
cell requires that it has the capacity to self-renew and that it
possesses potency. Self-renewal is defined as the ability of the
stem cell to go through multiple cycles of cell division while
maintaining its undifferentiated state (i.e., to generate daugh-
ter cells that are identical to it). Potency refers to the ability of
the stem cell to differentiate into specialized cell types (Wilmut
et al., 1997; Shamblott et al., 1998; Thomson et al., 1998). Stem
cell biology, when exploited along with molecular signaling and
biological approaches including calcium imaging, genomics, pro-
teomics, and metabolomics, can be utilized to enhance our under-
standing of complex biological processes such as apoptosis, and
can provide the fundamental concepts necessary for construct-
ing models of the building blocks of biological systems dur-
ing development. As these models evolve and become linked
together as integrative modules, they provide the intermediate
components necessary for use in a developmental toxicology
approach/platform.
A neural stem cell is a subclass of precursor cells that has sev-
eral specific characteristics: (1) self-renewing – capable of making
additional copies of itself by division; (2) multipotent – capable
of making daughter cells other than itself including committed
progenitors, neurons, astrocytes, and oligodendrocytes; and (3)
capable of generating all or part of neural tissue. Neural stem cells
or neural progenitor cells are generally uncommitted and so can
change their fate after exposure to salient environmental cues. Evi-
dence shows that gene expression and the capacity for self-renewal
and differentiation of neural stem cells are spatially and tempo-
rally specified. Thus, neural stem cells are defined as cells with the
ability to proliferate, self-renew, and produce a large number of
functional progeny that can differentiate into neurons, astrocytes,
or oligodendrocytes and this characteristic, thought to be con-
trolled by genomic, biochemical, and physical factors, is known as
multipotency (Wang et al., 1996; Park et al., 2005; Brokhman et al.,
2008).
The stem cell-derived models, especially human embryonic
neural stem cells with their capacity for proliferation and potential
for differentiation, have a great advantage for detecting potential
anesthetic-induced neurotoxicity. This system provides a reliable,
simple in vitro model, within a short time frame, for evaluating
potential adverse effects and investigating the cellular mechanisms
which may be associated with anesthetic-induced brain damage.
Thus, stem cell-derived models should be one of the best systems in
evaluating adverse effects of pediatric anesthetic exposure, because
of: (1) source (some embryonic neural stem cells are directly from
human fetuses); (2) specific cell types (the simplified in vitro sys-
tem allows for examining adverse effects of anesthetics directly
on neural stem cells, neurons, astrocytes, or oligodendrocytes; (3)
using minimal numbers of animals in a short time frame; and
(4) providing the opportunity for assessing the brain’s own regen-
erative capacity after experiencing events related to overdoses or
prolonged exposures to drugs including some general pediatric
anesthetics or environmental chemicals.
This review presents an overview of representative general anes-
thetics – primarily ketamine – as examples of how stem cells can
be valuable in identifying the doses and time-course over which
individual drugs produce damage and/or protect neural stem cells
and cells derived from them, change their proliferation rate, and
alter their fate (differentiation into neurons, oligodendrocytes,
and astrocytes) in vitro. Here, a strategy of the use of embry-
onic neural stem cell cultures for monitoring potential adverse
effects of ketamine on the neural stem cell expansion, proliferation,
differentiation, and receptor function has been defined.
Ketamine, a non-competitive NMDA receptor antagonist, is a
widely used general pediatric anesthetic agent. Lines of evidence
have demonstrated that ketamine causes neuronal cell death in
several major brain areas of experimental animals at an early devel-
opmental stage, e.g., during the brain growth spurt (Ikonomidou
et al., 1999; Scallet et al., 2004; Slikker et al., 2007; Zou et al.,
2009a). Apoptosis is a common cause of ketamine-induced neu-
ronal cell death in rodents (Zou et al., 2009b). Previous works
based on mRNA and protein levels have revealed that NMDA
receptor NR1 expression in ketamine-treated rat pup brain was
significantly higher than that in control rats (Slikker et al., 2007;
Zou et al., 2009b; Shi et al., 2010). This is indicative of a compen-
satory up-regulation of NMDA receptors on the neurons, along
with continued or prolonged NMDA receptor blockade by NMDA
antagonists (e.g., ketamine). Previous evidence suggested that
upon removal of ketamine from the extracellular milieu, the now
up-regulated NMDA receptor population (compensatory regula-
tion as a consequence of continued or prolonged NMDA receptor
blockade) will “over” respond to normal levels of extracellular glu-
tamate, resulting in glutamatergic excitotoxicity. However, several
important questions remain unanswered.
NMDA receptors constitute a sub-family of glutamate receptors
identified by specific molecular composition and pharmacological
and functional properties. NMDA receptors are densely localized
on neurons of most major brain areas and are physically con-
nected to proteins involved in cell-signaling cascades (Arundine
and Tymianski, 2003; Arundine et al., 2003). Glutamate is the pri-
mary excitatory neurotransmitter in the CNS of mammals. In
addition to ionotropic receptors responsible for fast excitatory
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neurotransmission in the CNS, glutamate also activates a num-
ber of metabotropic glutamate (mGlu) receptors, which belong
to the G-protein coupled receptor family of receptors. Glutamate
stimulates the opening of the channels that the ionotropic recep-
tors regulate to enable the influx of various ions and excessive
activation of NMDA-type glutamate receptors is implicated in
the pathophysiology of several neurological conditions includ-
ing hypoxia-ischemia and seizure-mediated excitotoxic damage,
neuropathic pain, and opiate dependence. Exploring the mecha-
nisms by which anesthetic agents might disturb NMDA receptor
expression patterns should help identify avenues for protection or
prevention of potential anesthetic-induced neuronal damage.
Since NMDA receptors are highly calcium permeable, the inter-
actions between altered ionotropic receptors (e.g., compensatory
up-regulation of NMDA receptor) and intracellular calcium sig-
naling [Ca2+]i, as well as how enhanced Ca2+ flux associated
with ketamine exposure influences reactive oxygen species (ROS)
generation and subsequent neuronal apoptosis, could appropri-
ately be clarified, by monitoring changes in intracellular calcium
concentration, e.g., Fura-2 AM live cell calcium imaging. Thus,
the relationship between anesthetic (ketamine)-induced NMDA
receptor dysregulation and signal transduction, could systemat-
ically be analyzed. Also, whether enhanced Ca2+ flux associated
with up-regulated NMDA receptors (as a consequence of keta-
mine exposure) could increase ROS generation and subsequent
neuronal apoptosis could be demonstrated.
The cartoon (above) indicates a potential specific involvement
of NMDA receptor-mediated excitation in ketamine-induced
neurotoxicity. Continuous blockade of NMDA receptors by
NMDA antagonists, such as ketamine, causes a compensatory up-
regulation of the NMDA receptor. This regulation could make cells
bearing the receptors more vulnerable, after ketamine washout, to
glutamate, because this up-regulation allows for a toxic accumu-
lation of intracellular calcium. Therefore, prolonged exposure of
neural stem cells to ketamine results in intracellular Ca2+ over-
load that exceeds the buffering capacity of the mitochondria and
interferes with electron transport in a manner that results in an
elevated production of ROS. Studies in vitro and in intact cells
have shown that caspase-3 specifically activates the endonuclease,
CAD (Caspase-Activated Deoxyribonuclease). CAD then degrades
chromosomal DNA within the nuclei and causes chromatin con-
densation. Also, ketamine may affect neural stem cell proliferation
by slowing down, or even stopping the cell cycle, finally resulting
in cell death.
Taken together, the use of neural stem cell models, especially
those of human origin, when combined with calcium imag-
ing and molecular biology approaches, holds promise for help-
ing to elucidate relevant mechanisms underlying the etiology
of the neurotoxicity associated with developmental exposures to
the general anesthetics, and may also help identify avenues of
protection or prevention. Data/observations related to NMDA
receptor expression and function could provide further support
to the idea, that in addition to NMDA-type glutamate recep-
tor expression levels, the specific signal transduction (e.g., Ca2+
influx) plays a critical role in anesthetic (ketamine)-induced
neurotoxicity.
APPLICATION OF NON-HUMAN PRIMATE MODELS (IN VIVO)
AND DYNAMIC MOLECULAR IMAGING APPROACHES TO
STUDYING ANESTHETIC-INDUCED NEUROTOXICITY
Recently described developmental neurotoxic insults involve the
apoptotic cell death of neurons in the rodent brain following
developmental exposure to sedatives and general anesthetics, such
as ketamine and some inhalation anesthetics (Jevtovic-Todorovic
et al., 2003; Scallet et al., 2004; Shi et al., 2010). When these com-
pounds are administered to the neonatal rat or mouse, a rapid and
significant increase in apoptosis occurs in several brain regions
(Young et al., 2005). Because of obvious concerns, it is not pos-
sible to thoroughly explore this kind of adverse anesthetic effect
on neurons in human infants or children, nor is it possible to
obtain relevant dose response or time-course data about the poten-
tial sedative/anesthetic-induced neuronal cell death and associated
behavioral deficits in humans.
The non-human primate is an animal model that has proved
invaluable for informing aspects of human physiology, pathology,
pharmacology, toxicology, and systems biology. No other com-
monly used research animal has a functional fetal-placental unit, a
propensity for single births and a fetal-to-maternal weight ratio
comparable to that of humans. Due to the complexity of the
primate brain, the monkey is often the animal of choice for neuro-
toxicology experiments and, given the protracted period of brain
development, the monkey is arguably the very best model for stud-
ies of developmental neurotoxicity. The phenomenon of interest
in the present discussion (anesthetic-induced neuronal cell death
in the brain) has also been previously observed in the non-human
primate, Macaca mulatta (Slikker et al., 2007; Zou et al., 2009a).
Thus, the relevance of the sedative/anesthetic-induced neuronal
cell death observed in rodent models to children is inferred because
similar effects occur in the developing non-human primate.
The first report regarding neuronal cell death in non-human
primates exposed perinatally to anesthetics was published in 2007
(Slikker et al., 2007). This study focused on the representative
general anesthetic, ketamine (a non-competitive NMDA receptor
antagonist), which was administered as an intravenous infusion
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at doses sufficient to produce a light surgical plane of anesthe-
sia (Slikker et al., 2007). The neurotoxic effects of these ketamine
exposures were examined several hours after the end of the infu-
sions, based on the hypothesis that ketamine (prolonged exposure)
induces an up-regulation of the NMDA receptor (compensatory),
causing neurons to be more vulnerable to the excitotoxic effects
of endogenous glutamate after ketamine has been cleared from
the system. A 24-h ketamine infusion in postnatal day (PND) 5
monkeys was shown to produce a large increase in the number of
darkly stained TUNEL-positive cells which exhibited the typical
nuclear condensation and fragmentation indicative of enhanced
apoptotic cell death. The TUNEL assay relies on the detection of
fragmented DNA strands.
The degree to which the nervous system is resistant to neuro-
toxic insults is highly dependent upon the stage of development.
Because the brain growth spurt in both human and non-human
primates extends over a much longer time period than in the rat,
matching the timing of a developmental event in humans and
non-human primates is less problematic than matching the same
between primates and rodents. In addition to PND 5 monkeys,
ketamine-induced neuronal degeneration was assessed in gesta-
tional day (GD) 122 and PND 35 monkeys (Slikker et al., 2007).
As seen in the PND 5 monkeys, GD 122 fetuses showed clear
ketamine-induced neuronal cell damage, whereas PND 35 mon-
keys did not. GD 122 fetuses and PND 5 monkeys, thus, are more
sensitive to ketamine-induced cell death than PND 35 monkeys,
when less synaptogenesis is occurring. Although a complete under-
standing of neuronal cell sensitivity to ketamine in the primate is
not possible from these few early studies, it is apparent that rhe-
sus monkeys are sensitive during the last 25% of gestation (term
is 165 days) to sometime before PND 35. Equating relative stages
of development between human and animal models is critical for
the extrapolation of safety assessment data. It is generally believed
that the non-human primate fetus (especially that of the rhesus
monkey) and the human fetus are more similar in stage of mat-
uration at birth as compared to rats that are relatively immature
at birth. For example, both humans and rhesus monkeys are born
with their eyes open at birth, whereas newborn rat pups are not.
At PND 7 the rat pup is more similar in maturation to a mon-
key late in gestation than to an infant monkey. According to a
recent review (Clancy et al., 2007), the GD 123 monkey fetus is
roughly equivalent to a GD 199 human fetus as determined by
cortical development, and both are in the range of 75–80% of
normal term. Also, NMDA receptor binding sites are present in
the human fetal brain by GD 115, increase until GD 140–150, and
then decrease slightly by GD 168–182 (Haberny et al., 2002) and
the localization of NMDA receptors in monkey cortex is similar to
that observed in humans (Huntley et al., 1997).
Recent research efforts employing imaging techniques have
covered a wide spectrum ranging from basic insights into normal
physiology and disease processes to drug development (Eckel-
man, 2003). Molecular imaging using PET/CT is a state-of-the-art
modality capable of obtaining in vivo measurements of multi-
ple biological processes in various organs (Massoud and Gamb-
hir, 2003; Min and Gambhir, 2004). Therefore, imaging tech-
nology has great potential for advancing the understanding of
brain-related biological processes, including neuronal plasticity,
neuronal degeneration/regeneration, and neurotoxicity (Zhang
et al., 2009, 2011). Exposure of the developing mammal to NMDA-
type glutamate receptor antagonists (e.g., ketamine or phencycli-
dine) affects the endogenous NMDA receptor system, endogenous
neural stem cell expansion, proliferation, and differentiation, and
enhances neuronal cell death (Slikker et al., 2005). Based on
previous data, it is expected that by using microPET/CT instru-
mentation long-lasting pathological changes in animals associated
with general anesthetic exposure can be observed in living subjects
(in vivo).
A growing body of data indicates that molecular imaging with
isotope-labeled biomarkers (radiotracers) may help to detect neu-
rotoxicity in infants, young, and adult animals (Zhang et al.,
2009, 2011). The high-resolution positron emission tomography
scanner (microPET) can provide in vivo molecular imaging at a
sufficient resolution to resolve both major structures and neu-
ronal activities in the non-human primate brain. To determine
whether prolonged sedative/anesthetic exposure during develop-
ment is associated with subsequent long-term cognitive deficits,
anesthetic drug-induced neurodegeneration can be explored by
monitoring changes in the uptake (binding) of radiotracers (e.g.,
[18F]-Peripheral Benzodiazepine Receptor ligand, a biomarker of
neurotoxicity- and gliosis), in specific regions of interest in the
monkey brain.
Meanwhile, studies are underway to employ radioactive tracers
(PET) designed to target specific stem cell ligands so that their
anatomical locations (CT) can be determined and monitored.
In addressing critical questions about the relationships between
anesthetic-induced neurotoxicity and developmental stage at time
of exposure, these molecular imaging tools could be utilized to
monitor, in vivo, endogenous neural stem cell activity following
exposure to general anesthetics. Here, the radiotracer likely to
be useful in monitoring endogenous neural stem cell prolifera-
tion is 3′-deoxy-3′-[18F]-fluoro-l-thymidine ([18F]-FLT), one of
the most widely used radiotracers for imaging cell proliferation
(Shields et al., 1998). The synthesis of [18F]-FLT has recently been
described (Shields et al., 1998; Slikker et al., 2005). FLT, a thymi-
dine analog, is taken up by cells and phosphorylated by thymidine
kinase (TK) 1, leading to intracellular trapping. The phosphory-
lated FLT is trapped within cells without being incorporated into
the cellular DNA because it lacks a 3′-hydroxyl. TK 1 is a cytoso-
lic isozyme of TK and its activity closely parallels that of cellular
proliferation (Bading and Shields, 2008). Therefore, the retention
of [18F]-FLT within the cells represents an in vivo marker that can
be used for the visualization of cell proliferation.
It has recently been reported that [18F]-FLT was used in con-
junction with PET imaging for the non-invasive detection of
endogenous neural stem cell proliferation in the normal and
ischemic adult rat brain in vivo (Jacobs et al., 2007; Rueger et al.,
2010). Thus, [18F]-FLT in conjunction with PET imaging should
be applicable for use with both rodents and non-human primates
following exposure to ketamine. If such experiments are success-
ful, then similar studies should be possible with human infants
and children. There are also other tracer choices that might be use-
ful for visualizing endogenous neural stem cell proliferation. For
example, it has recently been reported that 11C-labeled 4′-methyl-
thiothymidine ([11C]-4DST) is a useful radiotracer for the in vivo
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PET imaging of cellular proliferation (Toyohara et al., 2006, 2008,
2011, 2012). The rationales for using this particular compound are
that it is resistant to degradation by thymidine phosphorylase and
is incorporated into DNA (Toyohara et al., 2011).
SUMMARY
It has been proposed that pediatric sedative/anesthesia-induced
neurotoxicity depends on the amount (dose) given, the duration
of the exposure, the route of administration, the receptor sub-
type activated, and the stage of the neural development at the
time of exposure. These factors are important because they can
help identify thresholds of exposure for producing neurotoxicity
in the developing nervous system. There are yet many questions to
answer before the findings of pediatric drug-induced neurotoxic-
ity observed in animals can be related to effects in humans. Also,
the threshold doses and exposure durations necessary for safe and
effective treatment, as well as possible protective strategies must
be determined.
Therefore, a thorough characterization of neural stem cells
(in vitro) and an appropriate application of cellular/molecular/
biochemical research approaches, including calcium imaging
(Ca2+ influx), are crucial for understanding the cellular processes
underlying the expression of, and sensitivity to, neurotoxicity. Such
information will be needed in order to increase the likelihood of
the clinical success of our attempts to develop effective rescue and
prevention strategies.
In addition, the utilization of the developing non-human pri-
mate, in vivo, with dynamic molecular imaging approaches as
applied to neurotoxicology should provide a framework on which
information can be arranged in the form of biological models
to be used for dissecting out mechanisms underlying toxico-
logical phenomena associated with exposure to compounds of
interest. Meanwhile, the relationships between anesthetic-induced
neurotoxicity and endogenous neural stem cell activity follow-
ing exposure to general anesthetics could be appropriately eluci-
dated. Critical data can be obtained non-invasively, repeatedly, and
quantitatively in the same subjects (Myers, 2001; Chatziioannou,
2002).
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